Interleukin 20: Difference between revisions
Content deleted Content added
Jerome Kohl (talk | contribs) |
m Open access bot: add pmc identifier to citation with #oabot. |
||
| Line 11: | Line 11: | ||
== Anti IL-20 == |
== Anti IL-20 == |
||
Anti-IL-20 monoclonal antibodies have been researched as clinical candidates for the treatment or prevention of psoriasis, rheumatoid arthritis, atherosclerosis, osteoporosis, and stroke.<ref>{{cite journal | vauthors = Kragstrup TW, Otkjaer K, Holm C, Jørgensen A, Hokland M, Iversen L, Deleuran B | title = The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy | journal = Cytokine | volume = 41 | issue = 1 | pages = 16–23 | date = Jan 2008 | pmid = 18061474 | doi = 10.1016/j.cyto.2007.10.004 }}</ref><ref>{{cite journal | vauthors = Hsu YH, Chen WY, Chan CH, Wu CH, Sun ZJ, Chang MS | title = Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss | journal = The Journal of Experimental Medicine | volume = 208 | issue = 9 | pages = 1849–61 | date = Aug 2011 | pmid = 21844205 | doi = 10.1084/jem.20102234 | pmc=3171097}}</ref><ref>{{cite journal|last1=Kragstrup|first1=Tue Wenzel|last2=Greisen|first2=Stinne Ravn|last3=Nielsen|first3=Morten Aagaard|last4=Rhodes|first4=Christopher|last5=Stengaard-Pedersen|first5=Kristian|last6=Hetland|first6=Merete Lund|last7=Hørslev-Petersen|first7=Kim|last8=Junker|first8=Peter|last9=Østergaard|first9=Mikkel|last10=Hvid|first10=Malene|last11=Vorup-Jensen|first11=Thomas|last12=Robinson|first12=William H.|last13=Sokolove|first13=Jeremy|last14=Deleuran|first14=Bent|title=The interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progression|journal=Arthritis Research & Therapy|date=11 March 2016|volume=18|issue=1|doi=10.1186/s13075-016-0964-7}}</ref> |
Anti-IL-20 monoclonal antibodies have been researched as clinical candidates for the treatment or prevention of psoriasis, rheumatoid arthritis, atherosclerosis, osteoporosis, and stroke.<ref>{{cite journal | vauthors = Kragstrup TW, Otkjaer K, Holm C, Jørgensen A, Hokland M, Iversen L, Deleuran B | title = The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy | journal = Cytokine | volume = 41 | issue = 1 | pages = 16–23 | date = Jan 2008 | pmid = 18061474 | doi = 10.1016/j.cyto.2007.10.004 }}</ref><ref>{{cite journal | vauthors = Hsu YH, Chen WY, Chan CH, Wu CH, Sun ZJ, Chang MS | title = Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss | journal = The Journal of Experimental Medicine | volume = 208 | issue = 9 | pages = 1849–61 | date = Aug 2011 | pmid = 21844205 | doi = 10.1084/jem.20102234 | pmc=3171097}}</ref><ref>{{cite journal|last1=Kragstrup|first1=Tue Wenzel|last2=Greisen|first2=Stinne Ravn|last3=Nielsen|first3=Morten Aagaard|last4=Rhodes|first4=Christopher|last5=Stengaard-Pedersen|first5=Kristian|last6=Hetland|first6=Merete Lund|last7=Hørslev-Petersen|first7=Kim|last8=Junker|first8=Peter|last9=Østergaard|first9=Mikkel|last10=Hvid|first10=Malene|last11=Vorup-Jensen|first11=Thomas|last12=Robinson|first12=William H.|last13=Sokolove|first13=Jeremy|last14=Deleuran|first14=Bent|title=The interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progression|journal=Arthritis Research & Therapy|date=11 March 2016|volume=18|issue=1|doi=10.1186/s13075-016-0964-7|pmc=4788924}}</ref> |
||
== References == |
== References == |
||
Revision as of 20:40, 6 April 2019
| IL20 | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Aliases | IL20, IL-20, IL10D, ZCYTO10, Interleukin 20 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| External IDs | OMIM: 605619; MGI: 1890473; HomoloGene: 10286; GeneCards: IL20; OMA:IL20 - orthologs | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Interleukin 20 (IL20) is a protein that in humans is encoded by the IL20 gene.[5] Interkeukin 20 also includes other cytokines, including IL-19, IL-20, IL-22, IL-24, and IL-26. Based on common structural and functional properties of IL-20's receptors and target cells, these cytokines constitute the same subfamily, IL-20.[6]
Function
The protein encoded by this gene is a cytokine structurally related to interleukin 10 (IL-10). This cytokine has been shown to transduce its signal through signal transducer and activator of transcription 3 (STAT3) in keratinocytes. A specific receptor for this cytokine is found to be expressed in skin and upregulated dramatically in psoriatic skin, suggesting a role for this protein in epidermal function and psoriasis.[5]
Interleukin-20 (IL-20) is a protein belonging to the IL-10 family of cytokines. IL-20 is produced by activated keratinocytes and monocytes and transmits an intracellular signal through two distinct cell-surface receptor complexes on keratinocytes and other epithelial cells. IL-20 regulates proliferation and differentiation of keratinocytes during inflammation, particularly inflammation associated with the skin. In addition, IL-20 also causes cell expansion of multipotential hematopoietic progenitor cells.[7]
Anti IL-20
Anti-IL-20 monoclonal antibodies have been researched as clinical candidates for the treatment or prevention of psoriasis, rheumatoid arthritis, atherosclerosis, osteoporosis, and stroke.[8][9][10]
References
- ^ a b c GRCh38: Ensembl release 89: ENSG00000162891 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000026416 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ a b "Entrez Gene: Interleukin 20".
- ^ Rutz S, Wang X, Ouyang W (Dec 2014). "The IL-20 subfamily of cytokines—from host defence to tissue homeostasis". Nature Reviews. Immunology. 14 (12): 783–95. doi:10.1038/nri3766. PMID 25421700.
- ^ Rich BE, Kupper TS (August 2006). "Interleukin 20". Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry. 5 (3): 243–250. doi:10.2174/187152306778017683.
- ^ Kragstrup TW, Otkjaer K, Holm C, Jørgensen A, Hokland M, Iversen L, Deleuran B (Jan 2008). "The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy". Cytokine. 41 (1): 16–23. doi:10.1016/j.cyto.2007.10.004. PMID 18061474.
- ^ Hsu YH, Chen WY, Chan CH, Wu CH, Sun ZJ, Chang MS (Aug 2011). "Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss". The Journal of Experimental Medicine. 208 (9): 1849–61. doi:10.1084/jem.20102234. PMC 3171097. PMID 21844205.
- ^ Kragstrup, Tue Wenzel; Greisen, Stinne Ravn; Nielsen, Morten Aagaard; Rhodes, Christopher; Stengaard-Pedersen, Kristian; Hetland, Merete Lund; Hørslev-Petersen, Kim; Junker, Peter; Østergaard, Mikkel; Hvid, Malene; Vorup-Jensen, Thomas; Robinson, William H.; Sokolove, Jeremy; Deleuran, Bent (11 March 2016). "The interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progression". Arthritis Research & Therapy. 18 (1). doi:10.1186/s13075-016-0964-7. PMC 4788924.
{{cite journal}}: CS1 maint: unflagged free DOI (link)
This article incorporates text from the United States National Library of Medicine, which is in the public domain.